

Revision date: 29-Nov-2007

Version: 1.4

Page 1 of 7

#### 1. **IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING**

Pfizer Inc **Pfizer Pharmaceuticals Group** 235 East 42nd Street New York, New York 10017 1-212-573-2222

**Emergency telephone number:** 

Contact E-Mail:

Pfizer Ltd **Ramsgate Road** Sandwich, Kent **CT13 9NJ** United Kingdom +00 44 (0)1304 616161

**Emergency telephone number:** CHEMTREC (24 hours): 1-800-424-9300 ChemSafe (24 hours): +44 (0)208 762 8322 pfizer-MSDS@pfizer.com

### Material Name: Micronized Colestipol Hydrochloride Tablets

Trade Name:	COLESTID; LESTID
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product for the treatment of high cholesterol (hyperlipidemia).

### 2. HAZARDS IDENTIFICATION

Appearance:	Light yellow tablets
Statement of Hazard:	Non-hazardous in accordance with international standards for workplace safety.
Additional Hazard Information: Short Term: Known Clinical Effects: EU Indication of danger:	Not acutely toxic . Not expected to cause skin irritation (based on components). Adverse effects most commonly reported in clinical use include gastrointestinal disturbances, constipation, abdominal pain flatulence, heartburn, diarrhea, nausea, and vomiting. Not classified
Australian Hazard Classification (NOHSC):	Non-Hazardous Substance. Non-Dangerous Goods.
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Colestipol Hydrochloride	37296-80-3	Not listed	Not Listed	88
Magnesium stearate	557-04-0	209-150-3	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	*
		EEC No. 418-260-2		

### Material Name: Micronized Colestipol Hydrochloride Tablets Revision date: 29-Nov-2007

Ingredient	CAS Numbe	r EU EINECS/ELINCS List	Classification	%
Cellulose acetate phthalate	9004-38-0	Not listed	Not Listed	*
Glycerol triacetate	102-76-1	203-051-9	Not Listed	*
Carnauba wax	8015-86-9	232-399-4	Not Listed	*
Hypromellose	9004-65-3	Not listed	Not Listed	*
Povidone	9003-39-8	Not listed	Not Listed	*
Additional Information:	* Proprietary Ingredient(s) indicated safety.	as hazardous have been asses	sed under standards	for workplace
4. FIRST AID MEASURES				
Eye Contact:	Flush with water while immediately.	nolding eyelids open for at least	15 minutes. Seek n	nedical attention
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.			
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.			
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.			
5. FIRE FIGHTING MEASURES				
Extinguishing Media:	Use carbon dioxide, dr	y chemical, or water spray.		
Hazardous Combustion Products:	Formation of toxic gases is possible during heating or fire.			
Fire Fighting Procedures:	During all fire fighting activities, wear appropriate protective equipment, including self- contained breathing apparatus.			
Fire / Explosion Hazards:	Not applicable			
6. ACCIDENTAL RELEASE ME	ASURES			
Health and Safety Precautions:	Personnel involved in o Section 8). Minimize e	lean-up should wear appropriat xposure.	e personal protective	equipment (see
Measures for Cleaning / Collecting:		pill if it is safe to do so. Collect n. A damp cloth or a filtered vac area thoroughly.		
Measures for Environmental Protections:	Place waste in an appr avoid environmental re	opriately labeled, sealed contair lease.	ner for disposal. Car	e should be taken to
Additional Consideration for Large Spills:		el should be evacuated from affe Clean up operations should on		
7. HANDLING AND STORAGE				
General Handling:	avoid breathing dust ar	on and accumulation. If tablets nd avoid contact with eyes, skin, rotective equipment (see Section	and clothing. When	

Material Name: Micronized Colestipol Hydrochloride Tablets Revision date: 29-Nov-2007

Storage Conditions:

Store as directed by product packaging.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Colestipol Hydrochloride Pfizer OEL TWA-8 Hr:		3000µg/m³	
Magnesium stearate ACGIH Threshold Limit Value Australia TWA Belgium OEL - TWA Ireland OEL - TWAs Lithuania OEL - TWA Portugal OEL - TWA	(TWA)	= 10 mg/m <sup>3</sup> TWA = 10 mg/m <sup>3</sup> TWA = 10 mg/m <sup>3</sup> TWA = 10 mg/m <sup>3</sup> TWA = 3 mg/m <sup>3</sup> IPRV = 10 mg/m <sup>3</sup> TWA	except stearates of toxic metals except lead stearate does not include stearates of toxic metals
Spain OEL - TWA Sweden OEL - TWAs		= 10 mg/m <sup>3</sup> VLA-E = 5 mg/m <sup>3</sup> LLV	ED not including stearates of toxic metals
Colloidal silicon dioxide Australia TWA Austria OEL - MAKs Czech Republic OEL - TWA Estonia OEL - TWA Germany - TRGS 900 - TWAs Ireland OEL - TWAs Latvia OEL - TWA OSHA - Final PELs - Table Z-3 Slovakia OEL - TWA Slovenia OEL - TWA	3 Mineral D:	= 2 mg/m <sup>3</sup> TWA = 4 mg/m <sup>3</sup> MAK = 0.1 mg/m <sup>3</sup> TWA = 4.0 mg/m <sup>3</sup> TWA = 2 mg/m <sup>3</sup> TWA = 4 mg/m <sup>3</sup> TWA = 2.4 mg/m <sup>3</sup> TWA = 6 mg/m <sup>3</sup> TWA = 1 mg/m <sup>3</sup> TWA = 4 mg/m <sup>3</sup> TWA = 4 mg/m <sup>3</sup> TWA = 4 mg/m <sup>3</sup> TWA	containing more than 70% SiO2 (quartz) containing 10-70% SiO2 (granite, mica) containing 2-10% SiO2 (copper sulfate ores) /m³ TWA
Engineering Controls:	room ventilation is adequ	ate unless the proce	primary means to control exposures. General ess generates dust, mist or fumes. Keep airborne ts listed above in this section.
Personal Protective Equipment:			
Hands: Eyes: Skin: Respiratory protection:	processing operations. Wear safety glasses or g Impervious protective clo for bulk processing opera If the applicable Occupat	oggles if eye contac thing is recommend itions. ional Exposure Limi	contact with drug product is possible and for bulk it is possible. ed if skin contact with drug product is possible and t (OEL) is exceeded, wear an appropriate o control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablets	Color:	Light yellow

Material Name: Micronized Colestipol Hydrochloride Tablets Revision date: 29-Nov-2007

Molecular Formula:

Mixture

Molecular Weight: Mixture

### **10. STABILITY AND REACTIVITY**

Stability:	Stable under normal conditions of use.
Conditions to Avoid:	None known
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers

### 11. TOXICOLOGICAL INFORMATION

General Information:	The information included in this section describes the potential hazards of the individual
	ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Colestipol Hydrochloride**

RatOralLD50>1000 mg/kgMouseOralLD50>1000 mg/kgRatIntraperitonealLD50>4000 mg/kgMouseIntraperitonealLD50>4000 mg/kg

#### Povidone

Rat Oral LD50 100 g/kg

#### Hypromellose

Rat Oral LD50 > 10,000 mg/kg

#### **Magnesium stearate**

 Rat
 Oral
 LD50
 > 2000 mg/kg

 Rat
 Inhalation
 LC50
 > 2000 mg/m³

 Acute Toxicity Comments:
 A greate

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

#### **Colestipol Hydrochloride**

Eye Irritation Rabbit Mild Skin Irritation Rabbit Non-irritating

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### **Colestipol Hydrochloride**

1 Month(s) Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose 14 Day(s) Rabbit Oral 4000 mg/kg/day NOAEL No effects at maximum dose 1 Month(s) Dog Oral 3000 mg/kg/day LOAEL None identified 18 Month(s) Rat Oral 2000 mg/kg/day NOAEL No effects at maximum dose 1 Year(s) Dog Oral 500 mg/kg/day LOAEL None identified

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Material Name: Micronized Colestipol Hydrochloride Tablets Revision date: 29-Nov-2007

Page 5 of 7 Version: 1.4

<b>Colestipol Hydrochloride</b> Reproductive & Fertility Rat Oral 1000 mg/kg/day NOAEL No effects at maximum dose Embryo / Fetal Development Rat Oral 1000 mg/kg/day NOAEL Not Teratogenic Embryo / Fetal Development Rabbit Oral 1000 mg/kg/day NOAEL Not Teratogenic			
<u>Genetic Toxicity: (Study Type, Cell Type/Organism, Result)</u>			
Colestipol Hydrochloride Bacterial Mutagenicity (Ames) Salmonella , E. coli Negative			
Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))			
<b>Colestipol Hydrochloride</b> 18 Month(s) Rat Oral 2000 mg/kg/day NOAEL Not carcinogenic			
Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below			
Povidone IARC: Group 3			
Colloidal silicon dioxide IARC: Group 3			

12. ECOLOGICAL INFORMATION		
Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.	

13. DISPOSAL CONSIDE	RATIONS	
Diamagal Dragaduraa	Dispass of waste is accordance with all applicable lows and regulations.	Manahan Ctata

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered.

### **14. TRANSPORT INFORMATION**

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## **15. REGULATORY INFORMATION**

EU Indication of danger:

Not classified

Material Name: Micronized Colestipol Hydrochloride Tablets Revision date: 29-Nov-2007

#### OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

#### Canada - WHMIS: Classifications

#### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Cellulose acetate phthalate Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Glycerol triacetate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 203-051-9
Carnauba wax Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 232-399-4
Hypromellose Inventory - United States TSCA - Sect. 8(b) Australia (AICS): Standard for the Uniform Scheduling for Drugs and Poisons:	XU Present Schedule 4
Magnesium stearate Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 209-150-3
Povidone Inventory - United States TSCA - Sect. 8(b) Australia (AICS):	XU Present
Colloidal silicon dioxide Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Present Present 231-545-4 EEC No. 418-260-2

Material Name: Micronized Colestipol Hydrochloride Tablets Revision date: 29-Nov-2007

### **16. OTHER INFORMATION**

Reasons for Revision:	Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 9 - Physical and Chemical Properties.
Prepared by:	Toxicology and Hazard Communication Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

#### Page 7 of 7 Version: 1.4